FCGR2A and neoplasm: Additionally, FcγR-independent therapeutics including anti-TNFR and anti-CD40 monoclonal antibodies with human IgG2 agonistic activity have been developed and have showed encouraging clinical outcomes in late stage tumor patients (51, 52).